This is the cold email plan we'd run for a medical communications agency focused on one therapy area or one kind of company. The timing is public. Trial phases and approvals and congress deadlines are all published.
Your market is every company developing or selling drugs or devices in your therapy area. ClinicalTrials.gov lists trials by company and phase. The FDA device database lists device makers.
These are the signals worth looking for.
ClinicalTrials.gov shows when a trial changes phase or finishes. Each milestone brings publications and presentations with it.
Completed trials need their results written up. Manuscripts and congress abstracts follow.
An FDA approval or clearance means launch material is needed right away.
Each therapy area has its big yearly meetings with abstract deadlines. The months before those deadlines are busy for anyone presenting.
Job posts for medical writers or publication managers on LinkedIn or Indeed mean the work is bigger than the team.
Crunchbase shows the round. A funded biotech moving into the clinic needs a publication plan.
Lead with the trial and its new phase.
Lead with the approval and the launch material it needs.
Lead with the congress and the deadline.
Lead with the job post and a faster way to get the work done.
Oncology and cardiology have different congresses and different journals. Keep them in separate campaigns.
From their ClinicalTrials.gov listings map out the manuscripts and congress abstracts each trial could produce over the next year. Include the deadlines.
It works because it turns their own pipeline into a to do list. Writing it is your job.
The major meetings in their therapy area for the next twelve months with the abstract deadline for each.
It works because the dates are fixed and easy to miss. A calendar with their trials placed on it makes the plan real.
Draft their next congress abstract free from the data they already have. Their medical and legal reviewers check it as they would any agency work.
It works because it is real work on their real data with a real deadline. The rest of the publication plan is the retainer.
Deliver the draft well before the abstract deadline.
Hi {{first_name}},
Saw {{trial_name}} moved to {{trial_phase}} on ClinicalTrials.gov.
We write for {{therapy_area}} companies only. Mapped out the publications and congress abstracts this trial could support over the next year.
Want the outline?
{{sender_first_name}}
Hi {{first_name}},
Congrats on the {{approval_type}} for {{product}}.
Launch material usually lands on medical affairs right after. Put together what we'd write first.
Worth a look?
{{sender_first_name}}
Hi {{first_name}},
We write publications and congress material for {{therapy_area}} companies.
{{proof_line}}
Worth a conversation?
{{sender_first_name}}
Swap {{proof_line}} for one real result of your own. An abstract accepted or a paper published. If there is no result yet then leave the line out.
At small biotechs the chief medical officer or the head of clinical decides. At bigger companies it is the head of medical affairs or publications. At device companies loop in marketing too.
Results depend on the offer and the list. Three outbound agencies that publish their own numbers land between one booked meeting per 1,000 people contacted and one per 2,000. One of them also tested 650,000 cold emails with a plain offer and got about 3 to 6 interested replies per 10,000 people.
Those are other people's numbers and not a promise about your market. Your market's number only comes from testing it.
We build and run this campaign for one agency per industry.
Thirty minutes on your market and how we'd reach it.